6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag?
6 voices in 10 minutes: Strategies to reduce cardiovascular risk in patients with diabetes mellitus When do we choose SGLT2i or GLP1ag? In recent years, there has been a paradigm shift in diabetes’ aims of treatment, going from glycocentricity to assessment of mortality reduction and cardiovascular...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2020-11-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://revistasad.com/index.php/diabetes/article/view/283 |
| _version_ | 1811319246516387840 |
|---|---|
| author | Cristina Faingold |
| author_facet | Cristina Faingold |
| author_sort | Cristina Faingold |
| collection | DOAJ |
| description | 6 voices in 10 minutes: Strategies to reduce cardiovascular risk in patients with diabetes mellitus
When do we choose SGLT2i or GLP1ag?
In recent years, there has been a paradigm shift in diabetes’ aims of treatment, going from glycocentricity to assessment of mortality reduction and cardiovascular risk (CVR).
Three different types of diabetes drugs have been subjected to tests for assessing CV results. Most of them were focused on high-risk CV populations and all drugs demonstrated NO risk increase by using them. Some drugs even showed significant benefits and also some unexpected benefits were found, such as renal protection. |
| first_indexed | 2024-04-13T12:39:25Z |
| format | Article |
| id | doaj.art-d94f4bc84103424fb72517984fed6e91 |
| institution | Directory Open Access Journal |
| issn | 0325-5247 2346-9420 |
| language | Spanish |
| last_indexed | 2024-04-13T12:39:25Z |
| publishDate | 2020-11-01 |
| publisher | Sello Editorial Lugones |
| record_format | Article |
| series | Revista de la Sociedad Argentina de Diabetes |
| spelling | doaj.art-d94f4bc84103424fb72517984fed6e912022-12-22T02:46:34ZspaSello Editorial LugonesRevista de la Sociedad Argentina de Diabetes0325-52472346-94202020-11-01543Sup161610.47196/diab.v54i3Sup.2832196 voices in 10 minutes: When do we choose SGLT2i or GLP1ag?Cristina Faingold0Unidad Asistencial Dr. César Milstein. Instituto Cardiovascular de Buenos Aires. Facultad de Medicina de la Universidad de Buenos Aires (UBA), Ciudad Autónoma de Buenos Aires, Argentina6 voices in 10 minutes: Strategies to reduce cardiovascular risk in patients with diabetes mellitus When do we choose SGLT2i or GLP1ag? In recent years, there has been a paradigm shift in diabetes’ aims of treatment, going from glycocentricity to assessment of mortality reduction and cardiovascular risk (CVR). Three different types of diabetes drugs have been subjected to tests for assessing CV results. Most of them were focused on high-risk CV populations and all drugs demonstrated NO risk increase by using them. Some drugs even showed significant benefits and also some unexpected benefits were found, such as renal protection.https://revistasad.com/index.php/diabetes/article/view/283diabetesriesgo cardiovascularfármacos |
| spellingShingle | Cristina Faingold 6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag? Revista de la Sociedad Argentina de Diabetes diabetes riesgo cardiovascular fármacos |
| title | 6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag? |
| title_full | 6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag? |
| title_fullStr | 6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag? |
| title_full_unstemmed | 6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag? |
| title_short | 6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag? |
| title_sort | 6 voices in 10 minutes when do we choose sglt2i or glp1ag |
| topic | diabetes riesgo cardiovascular fármacos |
| url | https://revistasad.com/index.php/diabetes/article/view/283 |
| work_keys_str_mv | AT cristinafaingold 6voicesin10minuteswhendowechoosesglt2iorglp1ag |